{
    "ticker": "URGN",
    "name": "UroGen Pharma Ltd.",
    "description": "UroGen Pharma Ltd. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for urological cancers and diseases. Founded in 2010 and headquartered in New York, UroGen aims to address unmet medical needs in the field of urology by leveraging its proprietary technology platform. The company is dedicated to advancing its lead product candidate, UGN-101, which is designed for the treatment of low-grade upper tract urothelial carcinoma (UTUC). UroGen's unique approach involves the use of sustained release formulations to improve patient outcomes while minimizing the need for invasive procedures. The company is committed to research and development, with a robust pipeline that includes additional candidates targeting various urological conditions. UroGen Pharma\u2019s mission is to provide patients with effective and less invasive treatment options, ultimately enhancing their quality of life. With a team of experienced professionals and a strong focus on innovation, UroGen is poised to make significant strides in the urological therapy landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "New York, New York, USA",
    "founded": "2010",
    "website": "https://www.urogen.com",
    "ceo": "Liz Barrett",
    "social_media": {
        "twitter": "https://twitter.com/UroGenPharma",
        "linkedin": "https://www.linkedin.com/company/urogen-pharma/"
    },
    "investor_relations": "https://investors.urogen.com",
    "key_executives": [
        {
            "name": "Liz Barrett",
            "position": "CEO"
        },
        {
            "name": "Jared Gollob",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Oncology Therapies",
            "products": [
                "UGN-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "UroGen Pharma Ltd. | Innovative Urology Treatments",
        "meta_description": "UroGen Pharma Ltd. is focused on developing innovative therapies for urological cancers and diseases. Discover their lead product and ongoing research initiatives.",
        "keywords": [
            "UroGen",
            "Urology",
            "Oncology",
            "Biopharmaceuticals",
            "UGN-101",
            "Urothelial Carcinoma"
        ]
    },
    "faq": [
        {
            "question": "What does UroGen Pharma focus on?",
            "answer": "UroGen Pharma focuses on developing innovative therapies for urological cancers and diseases."
        },
        {
            "question": "Who is the CEO of UroGen Pharma?",
            "answer": "Liz Barrett is the CEO of UroGen Pharma Ltd."
        },
        {
            "question": "Where is UroGen Pharma headquartered?",
            "answer": "UroGen Pharma is headquartered in New York, New York, USA."
        },
        {
            "question": "What is UroGen's lead product?",
            "answer": "UroGen's lead product is UGN-101, targeting low-grade upper tract urothelial carcinoma."
        },
        {
            "question": "When was UroGen Pharma founded?",
            "answer": "UroGen Pharma was founded in 2010."
        }
    ],
    "competitors": [
        "FGEN",
        "CRIS",
        "TGTX",
        "BLRX"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "ABBV",
        "BMY"
    ]
}